Overview: Why Retatrutide Results Matter
Retatrutide results from clinical trials represent the most significant weight reduction data of any metabolic peptide tested to date. Developed by Eli Lilly as a triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, retatrutide achieved a mean body weight reduction of -24.2% at its highest dose over 48 weeks — surpassing both semaglutide and tirzepatide in their respective pivotal trials.
These results are drawn from peer-reviewed publications in the New England Journal of Medicine and The Lancet. This article summarizes the key clinical trial findings, metabolic outcomes, body composition data, and safety profile that define retatrutide’s position in the research landscape. For a detailed breakdown of retatrutide’s mechanism and receptor pharmacology, see our Retatrutide Triple-Agonist Research Guide.
Phase 2 Obesity Trial Results (Jastreboff et al., 2023)
The landmark Phase 2 trial enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Participants were randomized to placebo or one of six retatrutide dose cohorts and treated for 48 weeks. The trial was published in the New England Journal of Medicine and represents the foundational dataset for retatrutide weight loss research. Full trial data is accessible via PubMed (PMID: 37436564).
Weight loss results by dose
| Dose Cohort | Mean Weight Loss (%) | Mean Weight Loss (kg) | % Achieving ≥15% Loss |
|---|---|---|---|
| Placebo | -2.1% | -2.2 kg | 3% |
| 1mg | -8.7% | -9.2 kg | 19% |
| 4mg (escalated) | -17.1% | -18.2 kg | 56% |
| 8mg (escalated) | -22.1% | -23.5 kg | 75% |
| 12mg (escalated) | -24.2% | -26.3 kg | 83% |
The most striking finding was that the 12mg cohort had not reached a weight loss plateau at 48 weeks — the weight loss curves were still declining, suggesting even greater reductions with extended treatment. This contrasts with semaglutide, which typically reaches plateau around 60-68 weeks.
What these numbers mean in context
The retatrutide results showing a -24.2% mean weight reduction translate to approximately 58 lbs (26.3 kg) for a 240 lb participant. For perspective, bariatric surgery (gastric bypass) typically produces 25-35% weight loss — retatrutide at its maximum dose is approaching surgical-level outcomes through pharmacological intervention alone. These retatrutide results position the compound as a potential non-surgical alternative in metabolic research. In the 12mg cohort, 83% of participants achieved at least 15% weight loss, and more than half exceeded 25%.
How Retatrutide Results Compare to Other GLP-1 Compounds
| Compound | Trial | Duration | Max Weight Loss | Plateau Reached? |
|---|---|---|---|---|
| Retatrutide 12mg | Phase 2 | 48 weeks | -24.2% | No |
| Tirzepatide 15mg | SURMOUNT-1 | 72 weeks | -22.5% | Approaching |
| Semaglutide 2.4mg | STEP 1 | 68 weeks | -16.0% | Yes |
| Liraglutide 3.0mg | SCALE | 56 weeks | -8.0% | Yes |
Retatrutide achieved greater weight loss in a shorter timeframe than any other compound, and it hadn’t plateaued. The comparison isn’t perfectly controlled — these are separate trials with different populations — but the magnitude of difference is noteworthy. For a deeper comparison, see our Semaglutide vs Retatrutide vs Tirzepatide Comparison.
The Glucagon Effect: Why Retatrutide Outperforms
The key differentiator in retatrutide’s results is the glucagon receptor activation — a pathway absent from semaglutide and tirzepatide. GLP-1 and GIP reduce food intake through appetite suppression and gastric slowing. Glucagon adds a third mechanism: increased energy expenditure through hepatic lipid oxidation and thermogenesis.
In simpler terms, semaglutide and tirzepatide primarily reduce caloric intake (you eat less). Retatrutide reduces caloric intake AND increases caloric output (you eat less and burn more). This dual-direction approach explains why retatrutide results showed greater weight loss in a shorter period without participants reaching a metabolic plateau where the body adapts and weight loss stalls. Research published by the National Institutes of Health highlights the significance of this multi-receptor approach in metabolic research.
Metabolic Outcomes Beyond Weight Loss
The clinical trials measured several metabolic parameters beyond body weight:
Glycemic control (Type 2 diabetes trial — Rosenstock et al., 2023)
A separate Phase 2 trial in participants with type 2 diabetes (published in The Lancet) demonstrated significant improvements in glucose metabolism. Mean HbA1c reductions ranged from -1.3% to -2.0% depending on dose — comparable to the most effective diabetes medications available. Fasting glucose levels improved across all dose groups, and insulin sensitivity markers showed meaningful improvement. This trial data is indexed on PubMed (PMID: 37224420).
Liver fat reduction
In a substudy of the obesity trial, participants treated with retatrutide 8mg and 12mg showed dramatic reductions in liver fat content. At 48 weeks, the mean relative reduction in liver fat exceeded 80% in the highest dose groups. Among participants who met criteria for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) at baseline, more than 80% in the 8mg and 12mg cohorts no longer met those criteria after treatment — effectively resolving their fatty liver disease.
Cardiovascular markers
Across dose cohorts, retatrutide treatment was associated with improvements in multiple cardiovascular risk factors including reductions in waist circumference, blood pressure, and triglyceride levels, with increases in HDL cholesterol. These improvements correlated with the degree of weight loss, further strengthening the cardiovascular case embedded in retatrutide results. The FDA’s clinical trial framework provides context for how Phase 2 metabolic data like this informs subsequent Phase 3 trial design.
Body Composition Data
One of the critical questions raised by retatrutide results is the composition of weight lost — specifically, what proportion is fat mass versus lean mass. In the Phase 2 trial, body composition was assessed using dual-energy X-ray absorptiometry (DEXA) in a subset of participants.
The data showed that approximately 75-80% of weight lost was fat mass, with 20-25% being lean mass. This ratio is consistent with — and may be slightly more favorable than — the body composition changes seen with semaglutide and tirzepatide. The preservation of lean mass is believed to be supported by retatrutide’s GIP receptor activity, which has been linked to muscle protein synthesis pathways in preclinical research. This body composition data forms one of the more underappreciated dimensions of retatrutide results. For broader context on how peptides influence body composition, see our guide to peptides for muscle growth and recovery.
Research Protocol Considerations for Retatrutide
For researchers studying retatrutide in preclinical or in vitro models, understanding the compound’s physicochemical properties is essential to experimental design. Retatrutide (LY3437943) has a molecular weight of approximately 4,812 Da and is typically supplied as a lyophilized powder requiring reconstitution in bacteriostatic water.
Recommended storage conditions for lyophilized retatrutide are -20°C for long-term stability, with reconstituted solutions stable at 4°C for up to 28 days when prepared under sterile conditions. The compound demonstrates pH-dependent solubility and should be reconstituted at physiological pH (6.5-7.5) for maximum stability. For detailed reconstitution methodology, researchers can reference our comprehensive peptide reconstitution guide.
Dose-escalation protocols used in the Phase 2 trial began at sub-therapeutic doses and escalated over 8-16 weeks, which is believed to minimize gastrointestinal adverse events. This escalation pattern is consistent with other GLP-1 receptor agonists and should be considered when designing preclinical study protocols that aim to replicate clinical pharmacokinetics.
Safety Profile
The most common adverse events documented across retatrutide results data were gastrointestinal in nature, with incidence increasing at higher doses:
- Nausea: 6-31% (dose-dependent), primarily during escalation periods
- Diarrhea: 6-25%, generally mild to moderate
- Vomiting: 0-16%, occurring mainly in the first weeks of each dose increase
- Decreased appetite: 3-19%, which contributed to the weight reduction effect
- Constipation: 3-12%, consistent with GLP-1 receptor-mediated gastric slowing
Serious adverse events were rare across all cohorts. Discontinuation rates due to adverse events ranged from 0-6% depending on the dose group, which is comparable to or lower than rates seen with semaglutide (7% in STEP 1) and tirzepatide (4-7% in SURMOUNT-1).
For a comprehensive overview of peptide-associated side effects, see our Peptide Side Effects: What Researchers Should Know.
Phase 3 Trials: What to Expect
Eli Lilly initiated Phase 3 clinical trials for retatrutide in 2024 under the TRIUMPH program. These larger, longer-duration studies will provide more definitive efficacy and safety data. Key Phase 3 trials include:
- TRIUMPH-1: Retatrutide for obesity without type 2 diabetes
- TRIUMPH-2: Retatrutide for type 2 diabetes
- TRIUMPH-3: Retatrutide for obesity with type 2 diabetes
- TRIUMPH-4: Retatrutide for metabolic dysfunction-associated steatohepatitis (MASH)
Results from these trials are expected between 2025 and 2027. If Phase 3 results confirm the Phase 2 findings, retatrutide could receive FDA approval as early as 2027-2028.
Key Takeaways from Retatrutide Results Research
Reviewing the full body of Phase 2 retatrutide results, several findings stand out as particularly significant for the research community. First, the dose-response relationship observed in retatrutide results is unusually steep — moving from 1mg to 12mg produces nearly a threefold increase in weight loss magnitude, from -8.7% to -24.2%. This suggests that maximizing receptor engagement across all three pathways yields compounding rather than additive benefits.
Second, retatrutide results demonstrate a durability advantage over existing GLP-1 compounds. Because weight was still declining at the 48-week endpoint in the highest dose cohort, researchers estimate that retatrutide results at 72 weeks could approach or exceed 30% mean body weight reduction — a threshold previously associated only with surgical intervention. This projection is speculative pending Phase 3 data but is supported by the trajectory of the published weight curves.
Third, the metabolic breadth of retatrutide results is notable. Unlike semaglutide, whose retatrutide results comparison shows primarily weight and glycemic effects, retatrutide simultaneously improves hepatic fat, cardiovascular markers, and body composition in ways that reflect its triple-receptor mechanism. Researchers studying cardiometabolic syndrome may find retatrutide results particularly informative given these multi-system improvements.
Finally, the safety data embedded in retatrutide results confirms that the tolerability profile is manageable. Discontinuation rates under 6% — even at the highest dose — indicate that the gastrointestinal burden, while present, is not prohibitive. This positions retatrutide results favorably for long-duration preclinical study designs.
Reconstitution for Research Use
PSPeptides carries research-grade retatrutide in multiple vial sizes (5mg, 10mg, 20mg, and 30mg), manufactured in the US with 99%+ purity verified via independent HPLC and mass spectrometry. Each vial comes with a batch-specific Certificate of Analysis.
For reconstitution instructions, see our How to Reconstitute Peptides Guide. For exact dosage volume calculations, use our free Peptide Reconstitution Calculator. For reconstitution, you’ll need Hospira Bacteriostatic Water and sterile laboratory syringes.
Frequently Asked Questions
How much weight can retatrutide help lose?
In Phase 2 clinical trials, the highest dose (12mg weekly) produced a mean weight loss of -24.2% over 48 weeks. At that point, weight was still declining — the curve had not plateaued, suggesting even greater reductions may be possible with longer treatment.
Is retatrutide more effective than semaglutide?
Based on available clinical data, retatrutide produced significantly greater weight loss (-24.2% at 48 weeks) than semaglutide (-16.0% at 68 weeks) in their respective trials. However, these are separate trials with different populations and cannot be directly compared with the same certainty as a head-to-head study.
When will retatrutide be FDA approved?
Phase 3 trials are underway through the TRIUMPH program. If results are positive, FDA approval could come as early as 2027-2028. Currently, retatrutide is available only as a research compound.
Are retatrutide results permanent?
Weight regain after discontinuation of GLP-1 class medications is well-documented — the STEP 1 extension trial showed that most weight lost on semaglutide was regained within a year of stopping treatment. Similar patterns are expected with retatrutide, though specific discontinuation data has not yet been published.
References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389(6):514-526. PubMed
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. Lancet. 2023;402(10401):529-544. PubMed
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(4):327-340.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
Buy Research-Grade Retatrutide — From $39.99 →
This content is for educational and research purposes only. All products are intended for laboratory research use only. Not for human consumption.
How much weight can you lose on retatrutide?
In the Phase 2 clinical trial published in the New England Journal of Medicine, retatrutide results showed participants losing an average of 24.2% of their body weight at the highest dose (12 mg) over 48 weeks. This translates to approximately 58 pounds for a 240-pound individual, making it the largest weight reduction observed in any obesity drug trial at that time. The retatrutide results demonstrated dose-dependent weight loss, with lower doses producing proportionally less but still clinically significant reductions.
How does retatrutide compare to Ozempic and Mounjaro?
Retatrutide results from clinical trials show approximately 24.2% weight loss at 48 weeks, compared to roughly 16% with semaglutide (Ozempic/Wegovy) and 22.5% with tirzepatide (Mounjaro/Zepbound) at their respective maximum doses. The key difference is that retatrutide is a triple-agonist targeting GLP-1, GIP, and glucagon receptors, while semaglutide targets only GLP-1 and tirzepatide targets GLP-1 and GIP. This additional glucagon receptor activation in retatrutide results in enhanced fat oxidation and energy expenditure beyond what the other two compounds achieve.
What are the side effects of retatrutide?
The most common side effects reported in retatrutide results from Phase 2 trials were gastrointestinal in nature, including nausea (affecting up to 45% of participants at higher doses), diarrhea, vomiting, and constipation. These GI side effects were most pronounced during dose escalation phases and generally decreased in severity over time. Retatrutide results also showed mild increases in heart rate and some injection site reactions, though serious adverse events were rare across all dose groups.
When will retatrutide be FDA approved?
As of 2026, retatrutide is still in Phase 3 clinical trials (the TRIUMPH program) and has not yet received FDA approval. Eli Lilly, the pharmaceutical company developing retatrutide, is conducting multiple large-scale trials evaluating its efficacy for obesity, type 2 diabetes, and metabolic-associated fatty liver disease. Based on typical drug development timelines and the promising retatrutide results from earlier phases, potential approval could come in late 2026 or 2027, though regulatory timelines can vary.
Does retatrutide reduce liver fat?
Yes, retatrutide results from clinical trials demonstrated remarkable reductions in liver fat content, with over 80% of participants achieving complete normalization of hepatic fat levels by week 48. This effect is attributed to retatrutide’s glucagon receptor agonism, which directly stimulates hepatic fat oxidation and reduces lipogenesis in the liver. The retatrutide results for liver fat reduction have led Eli Lilly to initiate dedicated trials for metabolic-associated steatotic liver disease (MASLD), formerly known as NAFLD.
What is the retatrutide mechanism of action?
Retatrutide works through simultaneous activation of three metabolic receptors: GLP-1 (which reduces appetite and improves insulin secretion), GIP (which enhances insulin sensitivity and influences fat storage), and glucagon (which increases energy expenditure and promotes hepatic fat oxidation). This triple-agonist mechanism is what distinguishes retatrutide results from single or dual agonist peptides, as each receptor pathway contributes unique metabolic benefits. The combined activation creates a synergistic effect on weight reduction, glycemic control, and liver fat metabolism.
Is retatrutide available for research?
Retatrutide is available from qualified research peptide suppliers for in vitro and preclinical laboratory research purposes. Research-grade retatrutide should meet 99%+ purity standards verified by third-party HPLC and mass spectrometry testing. It is important to note that retatrutide is an investigational compound not approved by the FDA for human use, and all research peptides are sold strictly for laboratory investigation—the clinical retatrutide results referenced in this article come from Eli Lilly’s regulated trials.
All PSPeptides products are sold exclusively for research and laboratory use.